A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
In participants with acetylcholine receptor antibody-positive or muscle-specific kinase antibody-positive generalized myasthenia gravis, inebilizumab improved function and reduced disease severity. (Funded by Amgen; MINT ClinicalTrial.gov number, NCT04524273.).
Authors
- John Vissing (ORCID: https://orcid.org/0000-0001-6144-8544)
- Nishi Rampal (ORCID: https://orcid.org/0009-0008-2285-0360)
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Mikhail Rojavin (ORCID: https://orcid.org/0000-0002-9010-2865)
- Michael Benatar (ORCID: https://orcid.org/0000-0003-4241-5135)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Emma Ciafaloni (ORCID: https://orcid.org/0000-0002-3925-3289)
- Yuehua Wu (ORCID: https://orcid.org/0000-0002-8858-1289)
- Qing Li (ORCID: https://orcid.org/0000-0002-2918-4945)
- Maria Isabel Leite (ORCID: https://orcid.org/0000-0003-4407-5066)
- Fengming Tang
- Richard J. Nowak
- Sue Cheng
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- Amgen (United States) (US)
- University of Miami (US)
- Rigshospitalet (DK)
- Yale University (US)
- University of Oxford (GB)
- National Hospital Organization Hanamaki Hospital (JP)
- University of Rochester (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1056/nejmoa2501561
- Citations
- 36
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 50.01
Funders
- Amgen